NEW ORLEANS -- In an interview at the Society of Nuclear Medicine and Molecular Imaging annual meeting, Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, discussed new appropriate use criteria for amyloid and tau PET imaging in Alzheimer’s disease patients.
Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines
Latest in Molecular Imaging
Radnostix to sell nuclear fuel processing assets for $13.5M
October 1, 2026
USC researchers develop “plug-and-play" platform for PET tracers
September 24, 2026
Telix inks deal to acquire ITM for $1.65B
September 21, 2026




















